ASAQ

ASAQ, the new fixed-dose combination (FDC) of artesunate (AS) and amodiaquine (AQ), was the first drug to be made available by DNDi in an innovative partnership with sanofi–aventis, in 2007.





The Malaria Partnership Newsletter,
November 2009

• a very simple, age-based dosing regimen
  - 1 tablet per day for 3 days for infants, children, and adolescents
  - 2 tablets once a day for 3 days for adults
  - Optimised dose ratio to avoid over- and –under-dosage
• ASAQ is the first FDC of the antimalarials, artesunate and amodiaquine, to be granted
• "prequalified" status by the WHO
  Now available and registered in 24 countries in sub-Saharan Africa
  5.3 millions treatments delivered in 2008; more than 20 millions to be distributed by end 2009

ASAQ in the media
The Washington Post, March 29, 2007: "A Dose of Innovation"

"I very much welcome the innovative ASAQ anti-malaria combination therapy. Due to this new medicine, less children will die unnecesarily in Africa because of malaria."
Bert Koenders, Development Cooperation Minister, Dutch Ministry of Foreign Affairs

Press release

• March, 2007: New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available

Scientific Publications
Malaria Journal Supplement 2010: Anti-malarial market and policy surveys in sub-Saharan Africa by Diap G, Amuasi J, Boakye I, Sevcsik A-M, and Pecoul B. Malaria Journal Supplement, BioMed Central 2010 April, 9(1):S1
The full article is available online.

Malaria Journal 2009: The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum by Sirima SB, Tiono AB, Gansané A, Diarra A, Ouédraogo A, Konaté AT, Kiechel JR, Morgan CC, Olliaro PL, Taylor WRJ. Malaria Journal 2009 Mar 16; 8:48.
The full article is available online.